{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:58:45Z","timestamp":1787630325915,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00296-020-04565-w","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T19:03:58Z","timestamp":1585767838000},"page":"703-710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease\u2014a randomised controlled trial"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2651-0864","authenticated-orcid":false,"given":"Nupoor","family":"Acharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8821-6652","authenticated-orcid":false,"given":"Shefali Khanna","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8411-2015","authenticated-orcid":false,"given":"Debashish","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3199-9163","authenticated-orcid":false,"given":"Sahajal","family":"Dhooria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-0694","authenticated-orcid":false,"given":"Varun","family":"Dhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0141-7655","authenticated-orcid":false,"given":"Sanjay","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"issue":"7","key":"4565_CR1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972\u20132002. Ann Rheum Dis 66(7):940\u2013944","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4565_CR2","first-page":"731","volume":"29","author":"R Giacomelli","year":"2002","unstructured":"Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML et al (2002) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 29(4):731\u2013736","journal-title":"J Rheumatol"},{"issue":"25","key":"4565_CR3","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655\u20132666","journal-title":"N Engl J Med"},{"issue":"9","key":"4565_CR4","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719","journal-title":"Lancet Respir Med"},{"issue":"1\u20133","key":"4565_CR5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","volume":"590","author":"H Oku","year":"2008","unstructured":"Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A et al (2008) Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590(1\u20133):400\u2013408","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"4565_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0014-2999(02)01758-2","volume":"446","author":"H Nakazato","year":"2002","unstructured":"Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R (2002) A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-\u03b1 at the translational level. Eur J Pharmacol 446(1):177\u2013185","journal-title":"Eur J Pharmacol"},{"issue":"9779","key":"4565_CR7","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377(9779):1760\u20131769","journal-title":"Lancet"},{"issue":"22","key":"4565_CR8","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370(22):2083\u20132092","journal-title":"N Engl J Med"},{"issue":"8","key":"4565_CR9","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/art.38702","volume":"66","author":"EL Herzog","year":"2014","unstructured":"Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider F, Varga J (2014) Interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis. Arthritis Rheumatol Hoboken NJ 66(8):1967\u20131978","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"11","key":"4565_CR10","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","volume":"62","author":"D Mukerjee","year":"2003","unstructured":"Mukerjee D, George DS, Coleiro B, Knight C, Denton CP, Davar J et al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62(11):1088\u20131093","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4565_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5301\/jsrd.5000231","volume":"2","author":"D Khanna","year":"2017","unstructured":"Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L et al (2017) Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord 2(1):11\u201318","journal-title":"J Scleroderma Relat Disord"},{"issue":"6","key":"4565_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1378\/chest.85.6.751","volume":"85","author":"DA Mahler","year":"1984","unstructured":"Mahler DA, Weinberg DH, Wells CK, Feinstein AR (1984) The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85(6):751\u2013758","journal-title":"Chest"},{"issue":"9790","key":"4565_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J et al (2011) Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378(9790):498\u2013506","journal-title":"Lancet"},{"issue":"1","key":"4565_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B et al (2018) Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 378(1):35\u201347","journal-title":"N Engl J Med"},{"issue":"1","key":"4565_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/0970-2113.148451","volume":"32","author":"ZF Udwadia","year":"2015","unstructured":"Udwadia ZF, Mullerpattan JB, Balakrishnan C, Richeldi L (2015) Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India Off Organ Indian Chest Soc 32(1):50\u201352","journal-title":"Lung India Off Organ Indian Chest Soc"},{"key":"4565_CR16","first-page":"P3652","volume":"40","author":"Y Miura","year":"2012","unstructured":"Miura Y, Tsunoda Y, Tanaka T, Takoi H, Yatagai Y, Rin S et al (2012) The efficacy of pirfenidone in scleroderma related interstitial lung disease. Eur Respir J 40:P3652","journal-title":"Eur Respir J"},{"issue":"9","key":"4565_CR17","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","volume":"171","author":"A Azuma","year":"2005","unstructured":"Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K et al (2005) Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171(9):1040\u20131047","journal-title":"Am J Respir Crit Care Med"},{"key":"4565_CR18","doi-asserted-by":"crossref","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al (2019) Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med","DOI":"10.1056\/NEJMoa1908681"},{"key":"4565_CR19","doi-asserted-by":"crossref","unstructured":"Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, et al (2016) An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial. J Rheumatol. jrheum.151322.","DOI":"10.3899\/jrheum.151322"},{"issue":"Suppl 55","key":"4565_CR20","first-page":"174","volume":"38","author":"U Costabel","year":"2011","unstructured":"Costabel U, Albera C, Cohen A, Bradford W, King T, Noble P et al (2011) The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): interim data from the RECAP extension study. Eur Respir J 38(Suppl 55):174","journal-title":"Eur Respir J"},{"issue":"1","key":"4565_CR21","doi-asserted-by":"publisher","first-page":"32608","DOI":"10.3402\/ecrj.v3.32608","volume":"3","author":"GN Salih","year":"2016","unstructured":"Salih GN, Shaker SB, Madsen HD, Bendstrup E (2016) Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results. Eur Clin Respir J 3(1):32608","journal-title":"Eur Clin Respir J"},{"issue":"7","key":"4565_CR22","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.rmed.2015.04.010","volume":"109","author":"S Harari","year":"2015","unstructured":"Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A et al (2015) Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study. Respir Med 109(7):904\u2013913","journal-title":"Respir Med"},{"issue":"5","key":"4565_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2169\/internalmedicine.55.5272","volume":"55","author":"M Bando","year":"2016","unstructured":"Bando M, Yamauchi H, Ogura T, Taniguchi H, Watanabe K, Azuma A et al (2016) Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis. Intern Med 55(5):443\u2013448","journal-title":"Intern Med"},{"key":"4565_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3389\/fmed.2017.00213","volume":"4","author":"A Tzouvelekis","year":"2017","unstructured":"Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E et al (2017) Longitudinal \u201cReal-World\u201d outcomes of pirfenidone in idiopathic pulmonary fibrosis in Greece. Front Med 4:213","journal-title":"Front Med"},{"issue":"3","key":"4565_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/resp.13145","volume":"23","author":"M Uehara","year":"2018","unstructured":"Uehara M, Enomoto N, Oyama Y, Suzuki Y, Kono M, Furuhashi K et al (2018) Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia. Respirology 23(3):318\u2013324","journal-title":"Respirology"},{"issue":"Suppl 58","key":"4565_CR26","first-page":"P763","volume":"44","author":"K Hostettler","year":"2014","unstructured":"Hostettler K, Zhong J, Tamm M, Lardinois D, Roth M (2014) Effect of pirfenidone on TGF-\u03b2-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis. Eur Respir J 44(Suppl 58):P763","journal-title":"Eur Respir J"},{"issue":"26","key":"4565_CR27","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380(26):2518\u20132528","journal-title":"N Engl J Med"},{"issue":"10","key":"4565_CR28","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","volume":"55","author":"CP Denton","year":"2016","unstructured":"Denton CP, Hughes M, Gak N, Vila J, Buch MH, Chakravarty K et al (2016) BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatol Oxf Engl 55(10):1906\u20131910","journal-title":"Rheumatol Oxf Engl"},{"issue":"8","key":"4565_CR29","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327\u20131339","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04565-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-020-04565-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04565-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T19:18:50Z","timestamp":1617218330000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-020-04565-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4565"],"URL":"https:\/\/doi.org\/10.1007\/s00296-020-04565-w","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]},"assertion":[{"value":"15 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}